CytoDyn (OTCQB: CYDY) has announced that leronlimab will be evaluated in two new metastatic triple-negative breast cancer regimens within clinical research organization Quantum Leap Healthcare Collaborative’s...
Conexeu Sciences (NASDAQ: CNXU) has launched a human collagen program at its Vancouver research and development facility for regenerative aesthetics, starting with the production of its first pilot batch of human type I...
Modular Medical (NASDAQ: MODD) has announced the completion of an extensive market research study conducted with cardiometabolic patient insights company closely held Thrivable to evaluate perceptions of Modular...
Faeth Therapeutics (NASDAQ: FTH) has reported preliminary Phase 2 clinical results showing a confirmed objective response rate of 33% for its investigational PIKTOR treatment combined with paclitaxel in patients with...
Kyverna Therapeutics (NASDAQ: KYTX) has announced the publication of the primary analysis of KYSA-8, its registrational trial of miv-cel (mivocabtagene autoleucel, KYV-101) in patients with stiff person syndrome (SPS)...
In a recent LinkedIn post, Dr. Riam Shammaa, CEO of closely held Cell Technologies, and co-author of a recently published paper in Frontiers in Immunology, highlighted findings from an investigation into whether...
Azora Therapeutics (NASDAQ: AZR) has announced the formation of a five-member board of directors comprising individuals with extensive drug development experience, a track record of FDA approvals, public-company...
Opus Genetics (NASDAQ: IRD) has announced the completion of dosing in the higher-dose Cohort 2 of BIRD-1, its ongoing Phase 1/2 clinical trial evaluating OPGx-BEST1 in patients with BEST1-related retinal diseases...
Altimmune (NASDAQ: ALT) has announced that a late-breaking abstract featuring results from the RECLAIM Phase 2 trial evaluating pemvidutide in adults with moderate-to-severe alcohol use disorder (AUD) has been accepted...
Analysts for Raymond James and Lake Street Capital Markets say the CMS Final Rule released last evening is a win for Profound Medical (NASDAQ:PROF; TSX:PRN), confirming “very strong reimbursement” for the company’s...